147 related articles for article (PubMed ID: 1701371)
1. Effects of luteinizing hormone, insulin, insulin-like growth factor-I and insulin-like growth factor small binding protein 1 in the polycystic ovary syndrome.
Conway GS; Jacobs HS; Holly JM; Wass JA
Clin Endocrinol (Oxf); 1990 Nov; 33(5):593-603. PubMed ID: 1701371
[TBL] [Abstract][Full Text] [Related]
2. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features.
Morales AJ; Laughlin GA; Bützow T; Maheshwari H; Baumann G; Yen SS
J Clin Endocrinol Metab; 1996 Aug; 81(8):2854-64. PubMed ID: 8768842
[TBL] [Abstract][Full Text] [Related]
3. Oral contraceptives increase insulin-like growth factor binding protein-1 concentration in women with polycystic ovarian disease.
Suikkari AM; Tiitinen A; Stenman UH; Seppälä M; Laatikainen T
Fertil Steril; 1991 May; 55(5):895-9. PubMed ID: 1708731
[TBL] [Abstract][Full Text] [Related]
4. Alterations in the sensitivity of serum insulin-like growth factor 1 and insulin-like growth factor binding protein-3 to octreotide in polycystic ovary syndrome.
Morris RS; Carmina E; Vijod MA; Stanczyk FZ; Lobo RA
Fertil Steril; 1995 Apr; 63(4):742-6. PubMed ID: 7534239
[TBL] [Abstract][Full Text] [Related]
5. The role of insulin-like growth factor-1 (IGF-1) and IGF binding protein-1 (IGFBP-1) in the pathogenesis of polycystic ovary syndrome.
Homburg R; Pariente C; Lunenfeld B; Jacobs HS
Hum Reprod; 1992 Nov; 7(10):1379-83. PubMed ID: 1283982
[TBL] [Abstract][Full Text] [Related]
6. Overnight secretion pattern of growth hormone, sex hormone binding globulin, insulin-like growth factor-1 and its binding protein in obese and non-obese women with polycystic ovarian disease.
Insler V; Barash A; Shoham Z; Koistinen R; Seppala M; Hen M; Lunenfeld B; Zadik Z
Isr J Med Sci; 1994 Jan; 30(1):42-7. PubMed ID: 7511134
[TBL] [Abstract][Full Text] [Related]
7. Correlation of plasma insulin and insulin-like growth factor-I with indices of androgen transport and metabolism in women with polycystic ovary syndrome.
Sharp PS; Kiddy DS; Reed MJ; Anyaoku V; Johnston DG; Franks S
Clin Endocrinol (Oxf); 1991 Sep; 35(3):253-7. PubMed ID: 1742883
[TBL] [Abstract][Full Text] [Related]
8. The independent effects of polycystic ovary syndrome and obesity on serum concentrations of gonadotrophins and sex steroids in premenopausal women.
Holte J; Bergh T; Gennarelli G; Wide L
Clin Endocrinol (Oxf); 1994 Oct; 41(4):473-81. PubMed ID: 7955458
[TBL] [Abstract][Full Text] [Related]
9. Endocrine abnormalities in ovulatory women with polycystic ovaries on ultrasound.
Carmina E; Wong L; Chang L; Paulson RJ; Sauer MV; Stanczyk FZ; Lobo RA
Hum Reprod; 1997 May; 12(5):905-9. PubMed ID: 9194637
[TBL] [Abstract][Full Text] [Related]
10. Elevated serum levels of free insulin-like growth factor I in polycystic ovary syndrome.
Thierry van Dessel HJ; Lee PD; Faessen G; Fauser BC; Giudice LC
J Clin Endocrinol Metab; 1999 Sep; 84(9):3030-5. PubMed ID: 10487660
[TBL] [Abstract][Full Text] [Related]
11. Serum levels of insulin-like growth factor-1, IGF binding protein-1 and insulin and the response to human menopausal gonadotrophins in women with polycystic ovary syndrome.
Homburg R; Orvieto R; Bar-Hava I; Ben-Rafael Z
Hum Reprod; 1996 Apr; 11(4):716-9. PubMed ID: 8671313
[TBL] [Abstract][Full Text] [Related]
12. The effect of sequential administration of octreotide alone and octreotide/growth hormone simultaneously on buserelin stimulated ovarian steroid secretion in women with polycystic ovary syndrome.
Piaditis GP; Hatziioanidis AH; Trovas GP; Misichronis GS; Kounadi TG; Devetzaki OA; Andronis CK; Rangou DB; Chlouverakis CS
Clin Endocrinol (Oxf); 1996 Nov; 45(5):595-604. PubMed ID: 8977757
[TBL] [Abstract][Full Text] [Related]
13. Diurnal variation of sex hormone binding globulin and insulin-like growth factor binding protein-1 in women with polycystic ovary syndrome.
Hamilton-Fairley D; White D; Griffiths M; Anyaoku V; Koistinen R; Seppälä M; Franks S
Clin Endocrinol (Oxf); 1995 Aug; 43(2):159-65. PubMed ID: 7554310
[TBL] [Abstract][Full Text] [Related]
14. Circulating leptin concentrations in polycystic ovary syndrome: relation to anthropometric and metabolic parameters.
Chapman IM; Wittert GA; Norman RJ
Clin Endocrinol (Oxf); 1997 Feb; 46(2):175-81. PubMed ID: 9135699
[TBL] [Abstract][Full Text] [Related]
15. Amplified and orderly growth hormone secretion characterizes lean adolescents with polycystic ovary syndrome.
Garcia-Rudaz MC; Ropelato MG; Escobar ME; Veldhuis JD; Barontini M
Eur J Endocrinol; 2002 Aug; 147(2):207-16. PubMed ID: 12153742
[TBL] [Abstract][Full Text] [Related]
16. The relationship between circulating androgens, obesity, and hyperinsulinemia on serum insulin-like growth factor binding protein-1 in the polycystic ovarian syndrome.
Buyalos RP; Pekonen F; Halme JK; Judd HL; Rutanen EM
Am J Obstet Gynecol; 1995 Mar; 172(3):932-9. PubMed ID: 7534449
[TBL] [Abstract][Full Text] [Related]
17. Plasma levels of insulin-like growth factor-I and its binding protein in polycystic ovary syndrome.
Iwashita M; Mimuro T; Watanabe M; Setoyama T; Matsuo A; Adachi T; Takeda Y; Sakamoto S
Horm Res; 1990; 33 Suppl 2():21-6. PubMed ID: 1710201
[TBL] [Abstract][Full Text] [Related]
18. Metabolic features of polycystic ovary syndrome are found in adolescent girls with hyperandrogenism.
Apter D; Bützow T; Laughlin GA; Yen SS
J Clin Endocrinol Metab; 1995 Oct; 80(10):2966-73. PubMed ID: 7559882
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of insulin-like growth factor binding protein-1 and ovulatory responses to clomiphene citrate in women with polycystic ovarian disease.
Tiitinen AE; Laatikainen TJ; Seppälä MT
Fertil Steril; 1993 Jul; 60(1):58-62. PubMed ID: 7685718
[TBL] [Abstract][Full Text] [Related]
20. Androgen excess contributes to altered growth hormone/insulin-like growth factor-1 axis in nonobese women with polycystic ovary syndrome.
Wu X; Sallinen K; Zhou S; Su Y; Pöllänen P; Erkkola R
Fertil Steril; 2000 Apr; 73(4):730-4. PubMed ID: 10731533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
